—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Revolution Medicines Inc (RVMD) — chart, structure and Closelooknet read

The Closelooknet read

Revolution Medicines is a clinical-stage biotechnology company that designs drugs for cancers driven by mutated RAS proteins. Its lead candidate, daraxonrasib, sits in a late-stage trial for first-line pancreatic cancer alongside a second RAS-targeting compound, zoldonrasib.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RVMD, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sector × region Health care in US: +2.6% week · +9.8% month · +12.6% quarter · +32.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
How it trades on rate days beta 0.76 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RVMD has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.76 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Revolution Medicines Inc moved 0.76% on average · correlation 0.11 · higher than 66% of US names
  • Beta, last 3 months −0.42 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.55% on average against −0.72% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −3.54% TLT −1.32% that day 2026-11-10

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against RVMD on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Revolution Medicines Inc

RVMD in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Revolution Medicines is a clinical-stage biotechnology company that designs drugs for cancers driven by mutated RAS proteins. Its lead candidate, daraxonrasib, sits in a late-stage trial for first-line pancreatic cancer alongside a second RAS-targeting compound, zoldonrasib. Other candidates in its pipeline aim at different RAS mutations found in solid tumours. The company has no approved product yet and is based in Redwood City, California.
Where it sits in the stack
Revolution Medicines holds no seat in our index; it belongs to the biotech sleeve of the Healthcare sector we track, where the diary follows trial-stage drug developers for pipeline readouts rather than product sales.
Who it is priced against
Closelooknet's peer group places it among scored Healthcare names in the US — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics — because they share sector and country. The market also names Amgen, whose approved RAS inhibitor competes with the company's pipeline.
Why Closelooknet tracks it
It carries a Closelooknet score, our sector-neutral read across six modules, though it holds no index seat. Momentum reads strongest and quality reads weakest of those modules. The diary has not yet quoted the name in an edition.
What the diary watches
The diary watches how the phase 3 trial combining daraxonrasib and zoldonrasib in pancreatic cancer reads out, since a clinical result would move momentum and quality readings together.

Revolution Medicines Inc (RVMD) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 26/100 composite (momentum 78, quality 2, valuation 6) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 8 analyst actions on the wire · latest: price target by RBC Capital, 2026-10-08

The Street on this name

Analyst actions and the latest print for RVMD from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target RBC Capital — target 259 from 251 Target raised to $259 from $251 (+41.1% to spot) 2026-10-08
  • Price target Truist — target 240 from 239 Target raised to $240 from $239 (+19% to spot) 2026-10-07
  • Initiation Brookline Capital — at Buy Initiated to Buy 2026-09-28

8 actions on the analyst wire since 2026-08-13: 1 initiation, 7 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 8 m USD in FY2025

Dividends and capital return

What RVMD pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 8 m USD 0.0% of today's market value
  • Share count +13.3% in FY2025 118 m USD of stock-based compensation in the year
  • Capital returned 8 m USD in a year of negative free cash flow dividends and buybacks together

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is Revolution Medicines Inc (RVMD)?

Revolution Medicines Inc trades as RVMD on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is RVMD in a Closelooknet index?

Not currently — Revolution Medicines Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-11.

What is Revolution Medicines Inc's Closelooknet composite score?

26 out of 100, with momentum 78, quality 2 and valuation 6 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does RVMD trade against its moving averages?

Revolution Medicines Inc trades 1.7% below its 50-day and 21.6% above its 200-day moving average (1.8% above its 20-day). As of 2026-11-10 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Revolution Medicines Inc compare with its peers?

Against its peer group (Biotechnology · US), Revolution Medicines Inc (RVMD) sits 13.9% below its 52-week high, 1.7% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 23.1% below, BeOne Medicines AG (ONC) is 0.2% below, Regeneron Pharmaceuticals Inc (REGN) is 7.2% below, as of 2026-11-10. Put any of them next to RVMD in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Revolution Medicines Inc trade when bond yields rise?

Over the past year Revolution Medicines Inc had a beta of 0.76 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 66% of US names. On the 10 sessions in which long bonds fell most it moved −1.55% on average, against −0.72% for the S&P 500. As of 2026-11-10; The "How it trades on rate days" block on this page carries the lines.

What does Revolution Medicines Inc do?

Revolution Medicines is a clinical-stage biotechnology company that designs drugs for cancers driven by mutated RAS proteins. Its lead candidate, daraxonrasib, sits in a late-stage trial for first-line pancreatic cancer alongside a second RAS-targeting compound, zoldonrasib. Other candidates in its pipeline aim at different RAS mutations found in solid tumours. Closelooknet's peer group places it among scored Healthcare names in the US — argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics — because they share sector and country. The market also names Amgen, whose approved RAS inhibitor competes with the company's pipeline. (Company snapshot of 2026-09-17.)

Where does Revolution Medicines Inc sit in the AI build-out?

Revolution Medicines holds no seat in our index; it belongs to the biotech sleeve of the Healthcare sector we track, where the diary follows trial-stage drug developers for pipeline readouts rather than product sales. It carries a Closelooknet score, our sector-neutral read across six modules, though it holds no index seat. Momentum reads strongest and quality reads weakest of those modules. The diary has not yet quoted the name in an edition. (Company snapshot of 2026-09-17.)

Does Revolution Medicines Inc pay a dividend?

No cash distribution shows in Revolution Medicines Inc’s price series over the last three years. In fiscal 2025 the company bought back 8 m USD of its own shares. The share count rose 13.3% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Revolution Medicines Inc recently?

The most recent analyst action on Revolution Medicines Inc on the Closelooknet wire is a price target by RBC Capital on 2026-10-08 (target 259 from 251). 8 actions on the analyst wire since 2026-08-13: 1 initiation, 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RVMD, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.